Fennec Pharmaceuticals Inc. (FENC) Key Metrics
FENC valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $350.0M
- Enterprise value
- $344.6M
- P/E (TTM)
- —
- Forward P/E
- 10.6
- PEG ratio
- 1.47
- Price / sales
- 5.9 10-yr median 14.0
- Price / book
- 8.7 10-yr median 6.3
- EV / EBITDA
- 20.3 10-yr median 96.1
- Dividend yield
- —
- Beta
- 1.23
FENC key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsFENC valuation Price multiples at each fiscal year-end price.
Price / sales+35.8%
4.9
2025 · hover or tap a bar for each year
20162025
Price / book
6.3
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−21.3 pts
−5.7%
2025 · hover or tap a bar for each year
20162025
FENC returns How much profit the business earns on the capital it uses.
Return on equity
−66.8%
2025 · hover or tap a bar for each year
20162025
Return on assets−15.7 pts
−16.9%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−84.7 pts
−27.9%
2025 · hover or tap a bar for each year
20162025
Asset turnover−41.4%
0.78
2025 · hover or tap a bar for each year
20162025
FENC per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−10.3%
$1.56
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.34
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.44
2025 · hover or tap a bar for each year
20162025
Book value per share
$1.23
2025 · hover or tap a bar for each year
20162025
Shares outstanding+4.7%
28.6M
2025 · hover or tap a bar for each year
20162025
FENC financial health Debt, liquidity and how easily interest is covered.
Net debt−$29.4M
−$36.7M
2025 · hover or tap a bar for each year
20162025
Current ratio−0.6%
6.34
2025 · hover or tap a bar for each year
20162025
Interest coverage
-3.1
2025 · hover or tap a bar for each year
20162025
FENC efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+64 days
147 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−57 days
127 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−21 days
381 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+28 days
-107 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
FENC valuation history
Fiscal year-endToday10-year median
FENC returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
FENC debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
FENC cash returned to shareholders
DividendsBuybacksFree cash flow
FENC price vs earnings per share
Share price at year-endEPS (right axis)
FENC key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $220.0M | $172.5M | $298.2M | $252.2M | $114.4M | $176.6M | $129.1M | $121.3M | $150.4M | $27.3M |
| Enterprise value | $183.3M | $165.2M | $315.8M | $253.4M | $98.3M | $146.3M | $115.5M | $98.5M | $122.3M | $23.4M |
| Price / sales | 4.9 | 3.6 | 14.0 | 164.3 | 673.1 | — | — | — | — | — |
| Price / book | 6.3 | — | — | — | 7.3 | 6.1 | 10.9 | 5.7 | 5.6 | 7.6 |
| Price / free cash flow | — | 6.4 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | — | 6.4 | — | — | — | — | — | — | — | — |
| EV / sales | 4.1 | 3.5 | 14.9 | 165.1 | 578.4 | 860.3 | — | — | — | — |
| EV / EBITDA | — | 34.4 | — | — | — | — | — | 96.1 | — | 202.6 |
| EV / free cash flow | — | 6.1 | — | — | — | — | — | — | — | — |
| Earnings yield | −4.4% | −0.3% | −5.4% | −9.4% | −15.2% | −10.3% | −9.6% | −8.2% | −4.7% | −10.2% |
| Free cash flow yield | −5.7% | 15.6% | −5.7% | −7.2% | −12.4% | −8.8% | −7.0% | −6.5% | −2.4% | −7.8% |
| Dividend yield | — | — | — | 0.2% | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | 0.1% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $7.70 | $6.32 | $11.22 | $9.60 | $4.40 | $7.45 | $6.49 | $6.38 | $10.02 | $2.14 |
| Per share | ||||||||||
| Revenue per share | $1.56 | $1.74 | $0.80 | $0.06 | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.34 | −$0.02 | −$0.60 | −$0.90 | −$0.67 | −$0.76 | −$0.63 | −$0.52 | −$0.47 | −$0.22 |
| Operating cash flow per share | −$0.44 | $0.99 | −$0.65 | −$0.69 | −$0.55 | −$0.66 | −$0.46 | −$0.41 | −$0.24 | −$0.17 |
| Free cash flow per share | −$0.44 | $0.99 | −$0.65 | −$0.69 | −$0.55 | −$0.66 | −$0.46 | −$0.41 | −$0.24 | −$0.17 |
| Cash per share | $1.28 | $0.98 | $0.50 | $0.90 | $0.81 | $1.28 | $0.69 | $1.20 | $1.88 | $0.31 |
| Book value per share | $1.23 | −$0.22 | −$0.44 | −$0.10 | $0.61 | $1.23 | $0.60 | $1.12 | $1.78 | $0.28 |
| Tangible book value per share | $1.23 | −$0.22 | −$0.44 | −$0.10 | $0.61 | $1.23 | $0.60 | $1.12 | $1.78 | $0.28 |
| Dividends per share | — | — | — | $0.02 | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | $0.71 | $1.16 | $0.95 | $0.19 | — | — | — | $0.01 | $0.00 |
| Shares outstanding | 28.6M | 27.3M | 26.6M | 26.3M | 26.0M | 23.7M | 19.9M | 19.0M | 15.0M | 12.8M |
| Change in shares outstanding | +4.7% | +2.7% | +1.1% | +1.0% | +9.7% | +19.1% | +4.6% | +26.7% | +17.6% | +17.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −66.8% | — | — | — | −77.4% | −88.5% | −75.1% | −41.1% | −46.5% | −135.5% |
| Return on invested capital (ROIC) | — | — | −446.7% | — | — | — | — | — | — | — |
| Return on assets (ROA) | −16.9% | −1.2% | −59.6% | −96.1% | −64.4% | −79.5% | −67.2% | −38.5% | −43.5% | −111.8% |
| Return on tangible assets | −13.9% | −1.0% | −59.7% | −88.0% | −77.4% | −57.6% | −88.1% | −43.1% | −24.8% | −70.2% |
| Free cash flow margin | −27.9% | 56.8% | −80.7% | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | $19.3M | $31.0M | $24.9M | $5.0M | — | — | — | $167,000 | $33,000 |
| Cash & short-term investments | $36.7M | $26.6M | $13.3M | $23.8M | $21.1M | $30.3M | $13.7M | $22.8M | $28.3M | $3.9M |
| Net debt | −$36.7M | −$7.3M | $17.7M | $1.1M | −$16.1M | −$30.3M | −$13.7M | −$22.8M | −$28.1M | −$3.9M |
| Debt / equity | — | — | — | — | 0.32 | — | — | — | 0.01 | 0.01 |
| Debt / assets | — | 0.43 | 1.15 | 0.92 | 0.22 | — | — | — | 0.01 | 0.01 |
| Net debt / EBITDA | — | −1.52 | — | — | — | — | — | −22.22 | — | −33.69 |
| Current ratio | 6.34 | 6.38 | 3.56 | 5.80 | 13.54 | 13.39 | 6.11 | 14.02 | 17.28 | 9.88 |
| Quick ratio | 6.19 | 6.22 | 3.27 | 5.67 | 13.54 | 13.39 | 6.11 | 14.02 | 17.28 | 9.88 |
| Interest coverage | -3.1 | 0.6 | -3.8 | -23.2 | -136.7 | — | — | — | — | — |
| Working capital | $56.1M | $37.2M | $19.3M | $22.1M | $20.7M | $29.1M | $11.6M | $21.3M | $26.8M | $3.6M |
| Invested capital | −$1.7M | −$13.2M | $6.1M | −$1.4M | −$328,000 | −$1.3M | −$1.8M | −$1.5M | −$1.3M | −$323,000 |
| Tangible asset value | $35.1M | −$5.9M | −$11.6M | −$2.6M | $15.8M | $29.1M | $11.9M | $21.3M | $26.8M | $3.6M |
| Net current asset value | $31.5M | −$6.7M | −$11.6M | −$2.8M | $15.7M | $29.1M | $11.6M | $21.3M | $26.8M | $3.6M |
| Graham net-net per share | $0.70 | −$0.51 | −$0.66 | −$0.16 | $0.56 | $1.18 | $0.57 | $1.11 | $1.77 | $0.28 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $529,164 | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | $176,000 | $78,000 | $194,000 | $8,000 | $0 | $71,000 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | 0.7% | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Capex / operating cash flow | — | 0.0% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 15.8% | 10.6% | 25.2% | 274.9% | 2,361.8% | 1,641.8% | — | — | — | — |
| R&D / revenue | 0.6% | 0.6% | 0.3% | 230.0% | 2,930.0% | 3,002.9% | — | — | — | — |
| SG&A / revenue | 105.1% | 87.3% | 153.9% | 1,336.0% | 7,201.2% | 7,617.6% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 147.4 | 83.3 | 89.0 | 183.7 | 0.0 | — | — | — | — | — |
| Days of inventory on hand | 127.1 | 184.3 | 396.0 | 1,222.3 | — | — | — | — | — | — |
| Days payables outstanding | 381.5 | 402.3 | 894.1 | 6,720.7 | — | — | — | — | — | — |
| Cash conversion cycle (days) | -106.9 | -134.7 | -409.1 | -5,314.7 | — | — | — | — | — | — |
| Receivables turnover | 2.48 | 4.38 | 4.10 | 1.99 | — | — | — | — | — | — |
| Payables turnover | 0.96 | 0.91 | 0.41 | 0.05 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 2.87 | 1.98 | 0.92 | 0.30 | — | — | — | — | — | — |
| Asset turnover | 0.78 | 1.32 | 0.79 | 0.06 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $18.0M | $10.8M | $5.2M | $772,500 | $0 | — | — | — | — | — |
| Average payables | $3.9M | $3.5M | $3.1M | $1.6M | $1.2M | $1.6M | $1.3M | $943,500 | $549,500 | $270,500 |
| Average inventory | $1.3M | $1.6M | $1.4M | $288,000 | $0 | — | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from FENC's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
FENC valuation and financial ratios
Fennec Pharmaceuticals earned a return on equity of −66.8% in fiscal 2025. The share count rose 123.9% from 12.8M to 28.6M over 9 years.
See the FENC income statement, the FENC chart for price history, or the FENC stock overview for the latest quote and news.
FENC key metrics FAQ
What is Fennec Pharmaceuticals's return on equity?
Fennec Pharmaceuticals's return on equity (ROE) was −66.8% in fiscal 2025: net income of -$9.7 million on average shareholders' equity of $14.6 million.
What is Fennec Pharmaceuticals's free cash flow yield?
Fennec Pharmaceuticals generated -$12.5 million of free cash flow in fiscal 2025, a free cash flow yield of −5.7% on its market value at year-end ($220.0 million).
What is Fennec Pharmaceuticals's current ratio?
Fennec Pharmaceuticals's current ratio was 6.34 at the end of fiscal 2025: current assets were 6.34 times current liabilities.